Does night-to-night variability of sleep latency significantly predict the magnitude of subsequent change in sleep latency during placebo administration?
The importance of night-to-night variability of sSL in sleep assessment is highlighted. Excluding patients with high variability of lead-in sSL should be considered in clinical studies evaluating an effect on sleep onset, especially in the early stages of clinical development.
Patients who experience TSM transient severe motion during gadoxetate disodium-enhanced MR imaging are at significantly and substantially higher risk for TSM transient severe motion in the next gadoxetate disodium-enhanced examination compared with patients who do not have TSM transient severe motion during their initial gadoxetate disodium administration.